Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA.
Mol Diagn Ther. 2022 Nov;26(6):645-653. doi: 10.1007/s40291-022-00614-1. Epub 2022 Sep 30.
Pancreatic ductal adenocarcinoma (PDAC) is characterized by the occurrence of pathogenic variants in BRCA1/2 in 5-6% of patients. Biallelic loss of BRCA1/2 enriches for response to platinum agents and poly (ADP-ribose) polymerase 1 inhibitors. There is a dearth of evidence on the mechanism of inactivation of the wild-type BRCA1 allele in PDAC tumors with a germline BRCA1 (gBRCA1) pathogenic or likely pathogenic variant (P/LPV). Herein, we examine promotor hypermethylation as a "second hit" mechanism in patients with gBRCA1-PDAC.
We evaluated patients with PDAC who underwent Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) somatic and germline testing from an institutional database. DNA isolated from tumor tissue and matched normal peripheral blood were sequenced by MSK-IMPACT. In patients with gBRCA1-PDAC, we examined the somatic BRCA1 mutation status and promotor methylation status of the tumor BRCA1 allele via a methylation array analysis. In patients with sufficient remaining DNA, a second methylation analysis by pyrosequencing was performed.
Of 1012 patients with PDAC, 19 (1.9%) were identified to harbor a gBRCA1 P/LPV. Fifteen patients underwent a methylation array and the mean percentage of BRCA1 promotor methylation was 3.62%. In seven patients in whom sufficient DNA was available, subsequent pyrosequencing confirmed an unmethylated BRCA1 promotor. Loss of heterozygosity was detected in 12 of 19 (63%, 95% confidence interval 38-84) patients, demonstrating loss of heterozygosity is the major molecular mechanism of BRCA1 inactivation in PDAC. Two (10.5%) cases had a somatic BRCA1 mutation.
In patients with gBRCA1-P/LPV-PDAC, loss of heterozygosity is the main inactivating mechanism of the wild-type BRCA1 allele in the tumor, and methylation of the BRCA1 promoter is a distinctly uncommon occurrence.
胰腺导管腺癌(PDAC)的特征是 5-6%的患者发生 BRCA1/2 的致病性变异。BRCA1/2 的双等位基因缺失可增强对铂类药物和聚(ADP-核糖)聚合酶 1 抑制剂的反应。BRCA1 胚系致病性或可能致病性变异(P/LPV)的 PDAC 肿瘤中,野生型 BRCA1 等位基因失活的机制证据不足。在此,我们研究了 BRCA1 胚系阳性的 PDAC 患者中启动子超甲基化作为“二次打击”机制。
我们从机构数据库中评估了接受 Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets(MSK-IMPACT)体细胞和胚系检测的 PDAC 患者。MSK-IMPACT 通过 MSK-IMPACT 对肿瘤组织和匹配的外周血 DNA 进行测序。在 BRCA1 胚系阳性的 PDAC 患者中,我们通过甲基化阵列分析检测肿瘤 BRCA1 等位基因的体细胞 BRCA1 突变状态和启动子甲基化状态。在有足够剩余 DNA 的患者中,进行了第二次焦磷酸测序甲基化分析。
在 1012 例 PDAC 患者中,发现 19 例(1.9%)存在 BRCA1 P/LPV 胚系阳性。15 例患者进行了甲基化阵列分析,BRCA1 启动子甲基化的平均百分比为 3.62%。在 7 例有足够 DNA 的患者中,后续焦磷酸测序证实 BRCA1 启动子未甲基化。在 19 例患者中,12 例(63%,95%置信区间 38-84)检测到杂合性丢失,表明杂合性丢失是 PDAC 中 BRCA1 失活的主要分子机制。2 例(10.5%)患者存在体细胞 BRCA1 突变。
在 BRCA1 胚系阳性的 PDAC 患者中,杂合性丢失是肿瘤中野生型 BRCA1 等位基因失活的主要机制,BRCA1 启动子甲基化是一种明显罕见的发生。